Company intelligence / Profile preview
Pharmed Enterprises
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Pharmed Enterprises LLC develops small molecule drugs, with at least one program reaching Phase 3 clinical trials. Their pipeline includes candidates targeting cystitis, acute respiratory infections, metabolic syndrome, and influenza A virus infection. The company appears to focus on histamine receptor modulation among its mechanisms of action. No detailed published results or approvals were identified as of the latest data.
- Therapeutic areas
- Metabolic DisordersInfectious Diseases
- Modalities
- Small molecule drug
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Pharmed Enterprises.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmed Enterprises.